Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Taysha Gene Therapies, Inc.

Taysha GTx focuses on developing gene therapies for diseases of the central nervous system caused by the mutation of a single gene, known as monogenic diseases.

NASDAQ:TSHA

Taysha GTx

Last Close

2.06

25/09 14:39

Market Cap

455.12M

Beta: 1.17

Volume Today

213.04K

Avg: 417.73K

PE Ratio

−0.89

PFCF: −5.58

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics